Home > Boards > US Listed > Biotechs > United Therapeutics Corporation (UTHR)

5:31AM United Therapeutics: FREEDOM-C trial of oral treprostinil

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
surf1944 Member Profile
 
Followed By 435
Posts 26,254
Boards Moderated 2
Alias Born 09/11/06
160x600 placeholder
MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI™ With New Drug Application Acce... PR Newswire (US) - 6/16/2021 10:59:00 AM
United Therapeutics NDA for Tyvaso DPI to Get Priority Review Dow Jones News - 6/16/2021 6:30:00 AM
FDA grants accelerated review to United Therapeutics' Tyvaso DPI application Seeking Alpha - 6/16/2021 6:28:47 AM
MannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI™ With New Drug Application Acce... GlobeNewswire Inc. - 6/16/2021 6:15:00 AM
United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review PR Newswire (US) - 6/16/2021 6:00:00 AM
United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia PR Newswire (US) - 6/7/2021 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/3/2021 6:03:55 AM
United Therapeutics Announces First Patient Enrolled In Phase 3 TETON Study Of Tyvaso In Patients With Idiopathic Pulmonary F... PR Newswire (US) - 6/3/2021 6:00:00 AM
Specialized Disclosure Report (sd) Edgar (US Regulatory) - 6/1/2021 4:31:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/28/2021 4:42:57 PM
United Therapeutics Corporation To Present At The Jefferies Virtual Healthcare Conference PR Newswire (US) - 5/25/2021 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/12/2021 4:35:26 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/10/2021 4:33:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/10/2021 4:32:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/6/2021 4:41:05 PM
United Therapeutics EPS in-line, beats on revenue Seeking Alpha - 5/5/2021 6:01:28 AM
United Therapeutics Corporation Reports First Quarter 2021 Financial Results PR Newswire (US) - 5/5/2021 6:00:00 AM
United Therapeutics Q1 2021 Earnings Preview Seeking Alpha - 5/4/2021 1:00:01 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/29/2021 4:31:17 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/29/2021 6:47:34 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/29/2021 6:23:28 AM
United Therapeutics Corporation To Report First Quarter 2021 Financial Results Before The Market Opens On Wednesday, May 5, 2... PR Newswire (US) - 4/26/2021 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/22/2021 4:32:26 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/19/2021 6:04:37 AM
United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA PR Newswire (US) - 4/19/2021 6:00:00 AM
surf1944   Wednesday, 08/24/11 08:51:48 AM
Re: None
Post # of 26 
5:31AM United Therapeutics: FREEDOM-C trial of oral treprostinil in pulmonary arterial hypertension does not meet primary endpoint (UTHR) 48.76 : Co announces the completion of its FREEDOM-C Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension. Preliminary analysis demonstrates that the trial did not achieve statistical significance for the primary endpoint, six-minute walk distance at Week 16. Overall, 132 (84%) oral treprostinil and 138 (90%) placebo patients completed Week 16 with an average dose of 3.0 plus or minus 1.9 mg twice daily in the oral treprostinil group. Discontinuations due to adverse events were 18 (11%) and 5 (3%) in the treprostinil and placebo groups, respectively. Adverse events associated with discontinuations were typically prostacyclin-related effects including headache, nausea and vomiting. Preliminary analysis of other secondary efficacy measures, including time to clinical worsening, change in combined 6MWD and Borg Dyspnea Score rating and Dyspnea-Fatigue index, WHO functional class, and PAH signs and symptoms, did not differ significantly between oral treprostinil and placebo. Further review and analysis of the FREEDOM-C preliminary results are ongoing.


surf's up......crikey



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences